Search Results
Baxter to Present at the Goldman Sachs Healthcare Conference
Baxter International Inc. (NYSE: BAX) will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 in Rancho Palos Verdes, CA. José (Joe) E. Almeida, Baxter’s chairman and chief executive officer, is scheduled to present at 3:20 p.m. Pacific Daylight Time. The live webcast of Baxter’s presentation, can be accessed at www.baxter.com and will be available for replay through August 12, 2018.
Baxter to Host 2018 Investor Conference
Baxter International Inc. (NYSE: BAX) will host an investor conference on Monday, May 21, 2018 in New York City at the Pierre Hotel. The investor conference will feature an innovation hall displaying product and therapy advancements from Baxter’s pipeline beginning at 7:00 a.m. EDT, and will again be available following the conclusion of the formal presentations at 12:30 p.m. EDT. Presentations by members of the Baxter management team will commence at 8:00 a.m. EDT.
Baxter Announces U.S. FDA Clearance of New Spectrum IQ Infusion System
Baxter International Inc. (NYSE: BAX), a leader in innovative technology for medication delivery, today announced the U.S. Food and Drug Administration (FDA) clearance of the Spectrum IQ Infusion System with Dose IQ Safety Software.
Baxter Declares Dividend and Announces Quarterly Dividend Increase
Baxter International Inc. (NYSE:BAX) today announced an approximately 19% increase in the company’s quarterly dividend rate. This rate increase was made in connection with the declaration of a quarterly cash dividend of $0.19 per share of common stock (up from $0.16 per share), payable on July 2, 2018, to stockholders of record as of June 1, 2018. The indicated annual dividend rate is now $0.76 per share of common stock.
Baxter and the International Society of Nephrology Announce a Collaboration to Address Growing Prevalence of Kidney Disease
Baxter International Inc. (NYSE:BAX), a global innovator in renal (kidney) care, and the International Society of Nephrology (ISN) announced a partnership to advance chronic kidney disease (CKD) awareness and help improve access to therapy, particularly in low- and middle-income countries (LMIC) – commonly referenced as emerging markets – where the disease prevalence is growing the fastest.
Baxter Reports First-Quarter 2018 Results and Increases Financial Outlook for Full-Year 2018
Baxter International Inc. (NYSE: BAX) today reported results for the first quarter of 2018 and increased its full-year 2018 guidance.
Baxter International Inc. to Host Webcast of Annual Meeting of Shareholders
Baxter International Inc. (NYSE:BAX) will host a webcast of its Annual Meeting of Stockholders on Tuesday, May 8, 2018 at 9:00 a.m. Central Time. The live webcast of Baxter's presentation along with the accompanying slides can be accessed from Baxter’s website at www.baxter.com. The webcast will be recorded by Baxter and is copyrighted material, which cannot be recorded or rebroadcast without Baxter’s permission.
Baxter International Inc. to Host Webcast of Annual Meeting of Shareholders
Baxter International Inc. (NYSE:BAX) will host a webcast of its Annual Meeting of Stockholders on Tuesday, May 8, 2018 at 9:00 a.m. Central Time. The live webcast of Baxter's presentation along with the accompanying slides can be accessed from Baxter’s website at www.baxter.com. The webcast will be recorded by Baxter and is copyrighted material, which cannot be recorded or rebroadcast without Baxter’s permission.
Baxter Completes Acquistion of RECOTHROM and PREVELEAK to Broaden Surgical Hemostat and Sealant Portfolio
Baxter International Inc. (NYSE: BAX), a global medical products company, is committed to advancing surgical innovation and today announced it has completed its previously announced acquisition of two hemostat and sealant products from Mallinckrodt plc. RECOTHROM Thrombin topical (Recombinant) is the first and only stand-alone recombinant thrombin and PREVELEAK Surgical Sealant is used in vascular reconstruction.
Baxter Young Investigator Awards
Due to Baxter's planned spinoff of a new Kidney Care Company, the Baxter Young Investigator Awards program will pause for 2023 and return in 2024. We will reach out in the first quarter of 2024 with a call for applications that is aligned to the new organizational structure. Thank you for your interest.